ADCT News
ADC Therapeutics to Present at November Investor Conferences
ADC Therapeutics to Present at November Investor Conferences ADC Therapeutics to Present at November Investor ConferencesPR NewswireLAUSANNE, Switzerland, Nov. 3, 2026 LAUSANNE, Switzerland, Nov. 3, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer...
PR Newswire
ADC Therapeutics to Present at November Investor Conferences
ADC Therapeutics to Present at November Investor Conferences ADC Therapeutics to Present at November Investor ConferencesPR NewswireLAUSANNE, Switzerland, Nov. 3, 2026 LAUSANNE, Switzerland, Nov. 3, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer...
PR Newswire
ADC Therapeutics Announces New Employee Inducement Grant
ADC Therapeutics Announces New Employee Inducement Grant ADC Therapeutics Announces New Employee Inducement GrantPR NewswireLAUSANNE, Switzerland, Nov. 2, 2026 LAUSANNE, Switzerland, Nov. 2, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the...
PR Newswire
ADC Therapeutics to Announce Third Quarter 2026 Financial Results on November 9, 2026
ADC Therapeutics to Announce Third Quarter 2026 Financial Results on November 9, 2026 ADC Therapeutics to Announce Third Quarter 2026 Financial Results on November 9, 2026PR NewswireLAUSANNE, Switzerland, Nov. 2, 2026 LAUSANNE, Switzerland, Nov. 2, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE...
PR Newswire
ADC Therapeutics Announces ZYNLONTA Updates in Japan
ADC Therapeutics Announces ZYNLONTA Updates in Japan ADC Therapeutics Announces ZYNLONTA Updates in JapanPR NewswireLAUSANNE, Switzerland, Oct. 29, 2026 Licensing partner, Tanabe Pharma, filed for Japanese approval of ZYNLONTA (MT-2111) for relapsed or refractory DLBCL based on encouraging Japanese...
PR Newswire
NeoGenomics (NEO) Q3 Earnings and Revenues Beat Estimates
NeoGenomics (NEO) delivered earnings and revenue surprises of +16.67% and +0.66%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
ADC Therapeutics Announces Comprehensive Strategic Financial Restructuring Marking Key Capital Structure Improvements
ADC Therapeutics Announces Comprehensive Strategic Financial Restructuring Marking Key Capital Structure Improvements ADC Therapeutics Announces Comprehensive Strategic Financial Restructuring Marking Key Capital Structure ImprovementsPR NewswireLAUSANNE, Switzerland, Oct. 8, 2026$86.6 Million...
PR Newswire
ADC Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
ADC Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference ADC Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference PR Newswire LAUSANNE, Switzerland, Sept. 3, 2026 LAUSANNE, Switzerland, Sept. 3, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT...
PR Newswire
ADC Therapeutics (ADCT) Q2 2026 Earnings Call Transcript
@media (max-width: 768px) {
.image-container {
width: 100% !important;
float: none !important;
margin: 0 0 1rem 0 !important;
}
}
Image source: The Mo...
Nasdaq News: Markets
ADC Therapeutics Q2 2026 Earnings Call Transcript
On Thursday, ADC Therapeutics (NYSE:ADCT) discussed second-quarter financial results during its earnings call. The full transcript is provided below.
This content is powered by Benzinga APIs. For comprehensive financialread more...
Benzinga
ADC Therapeutics SA (ADCT) Reports Q2 Loss, Lags Revenue Estimates
ADC Therapeutics (ADCT) delivered earnings and revenue surprises of +42.11% and -4.48%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks